Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Updated safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; Flinn, I.; Tessoulin, B.; Shuo, M. A.; Alencar, A. J.; Lewis, D. J.; Woyach, J. A.; Maddocks, K. J.; Patel, K.; Wang, Y.; Rhodes, J.; Tam, C. S.; Seymour, J. F.; Nagai, H.; Vose, J. M.; Fakhri, B.; Hoffmann, M. S.; Hernandez-Ilizaliturr, F.; Zelenetz, A. D.; Kumar, A.; Munir, T.; Tsai, D.; Balbas, M.; Liu, B.; Ruppert, A. S.; Nguyen, B.; Roeker, L. E.; Wang, M. L.; Dreyling, M. |
| Abstract Title: | Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Updated safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study |
| Meeting Title: | 36. Deutscher Krebskongress - Fortschritt gemeinsam gestalten |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2024-02-01 |
| Start Page: | 119 |
| End Page: | 120 |
| Language: | English |
| ACCESSION: | WOS:001332646400284 |
| PROVIDER: | wos |
| DOI: | 10.1159/000535363 |
| Notes: | Meeting Abstract: 567 -- 'The 36th German Cancer Congress - Building Progress Together' -- Located in the section 'Hematooncology including Bone marrow transplantation, Lymphoma, Plasmocytoma' -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work